College of Pharmacy and Natural Products Research Institute, Seoul National University, Seoul 151-742, Republic of Korea.
Nanotechnology. 2013 Oct 4;24(39):395102. doi: 10.1088/0957-4484/24/39/395102. Epub 2013 Sep 5.
For topical applications in wound healing, silver nanoparticles (AgNPs) have attracted much attention as antibacterial agents. Herein, we describe a green-synthetic route for the production of biocompatible and crystalline AgNPs using two glycosaminoglycans, chondroitin sulfate (CS) and acharan sulfate (AS), as reducing agents. The synthetic approach avoids the use of toxic chemicals, and the yield of AgNPs formation is found to be 98.1% and 91.1% for the chondroitin sulfate-reduced silver nanoparticles (CS-AgNPs) and the acharan sulfate-reduced silver nanoparticles (AS-AgNPs), respectively. Nanoparticles with mostly spherical and amorphous shapes were observed, with an average diameter of 6.16 ± 2.26 nm for CS-AgNPs and 5.79 ± 3.10 nm for AS-AgNPs. Images of the CS-AgNPs obtained from atomic force microscopy revealed the self-assembled structure of CS was similar to a densely packed woven mat with AgNPs sprinkled on the CS. These nanoparticles were stable under cell culture conditions without any noticeable aggregation. An approximately 128-fold enhancement of the antibacterial activities of the AgNPs was observed against Enterobacter cloacae and Escherichia coli when compared to CS and AS alone. In addition, an in vivo animal model of wound healing activity was tested using mice that were subjected to deep incision wounds. In comparison to the controls, the ointments containing CS-AgNPs and AS-AgNPs stimulated wound closure under histological examination and accelerated the deposition of granulation tissue and collagen in the wound area. The wound healing activity of the ointments containing CS-AgNPs and AS-AgNPs are comparable to that of a commercial formulation of silver sulfadiazine even though the newly prepared ointments contain a lower silver concentration. Therefore, the newly prepared AgNPs demonstrate potential for use as an attractive biocompatible nanocomposite for topical applications in the treatment of wounds.
用于伤口愈合的局部应用，银纳米粒子（AgNPs）作为抗菌剂引起了广泛关注。本文描述了一种使用两种糖胺聚糖（硫酸软骨素（CS）和硫酸乙酰肝素（AS））作为还原剂生产生物相容和结晶 AgNPs 的绿色合成方法。该合成方法避免了使用有毒化学品，并且 CS 还原银纳米粒子（CS-AgNPs）和 AS 还原银纳米粒子（AS-AgNPs）的 AgNPs 形成产率分别为 98.1%和 91.1%。观察到具有大多为球形和无定形形状的纳米粒子，CS-AgNPs 的平均直径为 6.16±2.26nm，AS-AgNPs 的平均直径为 5.79±3.10nm。原子力显微镜获得的 CS-AgNPs 图像显示 CS 的自组装结构类似于紧密堆积的编织垫，AgNPs 洒在 CS 上。这些纳米粒子在细胞培养条件下稳定，没有任何明显的聚集。与 CS 和 AS 单独相比，AgNPs 对阴沟肠杆菌和大肠杆菌的抗菌活性增强了约 128 倍。此外，使用接受深切口伤口的小鼠测试了体内伤口愈合活性的动物模型。与对照组相比，含有 CS-AgNPs 和 AS-AgNPs 的软膏在组织学检查下刺激伤口闭合，并加速肉芽组织和胶原蛋白在伤口区域的沉积。含有 CS-AgNPs 和 AS-AgNPs 的软膏的伤口愈合活性与银磺胺嘧啶的商业制剂相当，尽管新制备的软膏含有较低的银浓度。因此，新制备的 AgNPs 具有作为有吸引力的生物相容纳米复合材料用于治疗伤口的局部应用的潜力。
